Expanding access to fertility care requires careful consideration of how benefits are designed, which services they cover, and their full costs to patients and health plans. A new white paper, The Cost of Assisted Reproductive Technology Treatments, reports findings from a retrospective actuarial analysis of commercial insurance claims examining costs associated with in vitro fertilization (IVF) and intrauterine insemination (IUI), including costs that may be overlooked in conventional benefit estimates.

This retrospective analysis of approximately five million commercially insured patients examines whether guideline-recommended infertility evaluations and treatments were completed before in vitro fertilization. The findings identify substantial care gaps and highlight the potential role of restorative reproductive medicine in supporting diagnosis-directed, comprehensive fertility care.

The International Institute for Restorative Reproductive Medicine presents a proposed definition of infertility and indications for fertility evaluation. The statement recognizes infertility as a clinical condition that points to underlying male and/or female pathology and considers factors including fertility-timed intercourse, pregnancy loss, reproductive health conditions, and age-related fertility decline.

The International Institute for Restorative Reproductive Medicine (IIRRM) is pleased to share a unique opportunity, Dr. Kim Couri and Dr. Louise Smyth—longtime IIRRM members and deeply committed restorative reproductive medicine clinicians—are preparing for retirement after many years of dedicated service to women, couples, and families. They are seeking a physician (or physicians) who is aligned with the mission of RRM and interested in continuing the established and thriving practice in Wisconsin.

A proposed rule – published May 13, 2026 by the Departments of Treasury, Labor, and HHS – would create a new category of “Excepted Fertility Benefits” in the U.S. allowing employers to offer fertility coverage separately from major medical insurance. While much of the public discussion around fertility benefits has focused on IVF, the proposed rule also includes language relevant to diagnosis, mitigation, and treatment of infertility and infertility-related reproductive health conditions. Read more and comment.

May 12, 2026 – Polycystic ovary syndrome (PCOS), a condition affecting approximately 1 in 8 women and more than 170 million people worldwide,1 has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a landmark global consensus process published in The Lancet.2 The new name was chosen to more accurately reflect the condition’s complex endocrine, metabolic, and ovarian features, while removing the misleading implication that the condition is primarily defined by ovarian “cysts.” The name change follows years of international work and a global consensus process involving patients, clinicians, researchers, and professional organizations across world regions. For many patients, the older term “PCOS” has contributed to confusion, delayed diagnosis, fragmented care, and a narrow focus on ovarian appearance rather than the broader hormonal and metabolic disturbances that often drive symptoms and long-term health risks. For those interested in the condition’s naming journey, this is not the first name change – it